Product Watch

Strides Arcolab gets USFDA approval for anti-bacterial injection

Views: 498

Drug firm Strides Arcolab said it has received the US health regulator’s approval to market injectable Clindamycin USP, used in the treatment of bacterial infections, in the American market.
The product will be available in three single-dose vial sizes and in pharmacy bulk packaging, Strides Arcolab said in a statement.
“The product is expected to be launched in early 2012,” it said, adding that the company received approval for its Clindamycin USP from the US Food and Drug Administration (USFDA).

Click to comment

Leave a Reply

Your email address will not be published.

Most Popular





Get Heard Portal


eHealth Event Report



To Top